BMY
Another myeloma win for BMS
Bristol Myers Squibb dropped fresh topline data from its Phase 3 EXCALIBER-RRMM trial, and the headline is pretty straightforward: Zenbexus (iberdomide) helped slash the risk of disease progression or death by 51% in patients with relapsed or refractory multiple myeloma.
The combo on deck was Zenbexus plus daratumumab and dexamethasone, and the company says the regimen delivered a median progression-free survival of 42 months versus 20 months for the standard comparator. That’s not a small flex; that’s the kind of result that can keep a drug’s commercial story buzzing.
Why investors care
A stronger late-stage readout can matter a lot more than a nice day-of pop in the share price. It helps BMS keep building the case for Zenbexus, especially after the FDA’s accelerated approval earlier this year gave the drug an early foothold in the market.
William Blair’s take was also pretty on-brand for the Street: oral Zenbexus could have an easier time in community practices, where access to CAR-T and bispecifics can be tougher. In other words, less sci-fi hospital theater, more practical prescription pad.
The fine print
- The study included about 800 patients, all at first relapse.
- Follow-up was a median 23 months.
- BMS said the safety profile lined up with earlier findings, which is always the line investors want to hear after a big efficacy headline.
Big picture: this doesn’t magically erase every BMY headache, but it does give the company another credible card to play in a crowded oncology deck.